Non-muscle-invasive bladder cancer (NMIBC) is an early-stage cancer without invasion into
the detrusor muscle layer. Transurethral resection of bladder tumour (TURBT) is a diagnostic …

Context In the management of urothelial carcinoma, determination of the pathological grade
aims at stratifying tumours into different prognostic groups to allow evaluation of treatment …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease with widely
different outcomes. We performed a comprehensive transcriptional analysis of 460 early …

Global mRNA expression analysis is efficient for phenotypic profiling of tumours, and has
been used to define molecular subtypes for almost every major tumour type. A key limitation …

Context Recent whole genome mRNA expression profiling studies revealed that bladder
cancers can be grouped into molecular subtypes, some of which share clinical properties …

The advent of Omics technologies has been key to the molecular subclassification of
urothelial bladder cancer. Several groups have used different strategies to this aim, with …

Global gene expression analysis has been a major tool for urothelial carcinoma subtype
discovery. This approach has revealed extensive complexity both in intrinsic features of the …

Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing
many of the genetic features of muscle-invasive bladder cancers, are classified as non …

Abstract High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non–muscle-
invasive bladder cancer with unpredictable outcome and poorly understood risk factors …